The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- Authors
- Rho, Jin Kyung; Choi, Yun Jung; Lee, Jin Kyung; Ryoo, Baek-Yeol; Il Na, Im; Yang, Sung Hyun; Lee, Seung Sook; Kim, Cheol Hyeon; Do Yoo, Young; Lee, Jae Cheol
- Issue Date
- Oct-2009
- Publisher
- AMER ASSOC CANCER RESEARCH
- Keywords
- CELL LUNG-CANCER; C-MET; ACQUIRED-RESISTANCE; CROSS-TALK; GEFITINIB; EGFR; MUTATION; METASTASIS; ERLOTINIB; INVASION
- Citation
- MOLECULAR CANCER RESEARCH, v.7, no.10, pp.1736 - 1743
- Indexed
- SCIE
SCOPUS
- Journal Title
- MOLECULAR CANCER RESEARCH
- Volume
- 7
- Number
- 10
- Start Page
- 1736
- End Page
- 1743
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/119204
- DOI
- 10.1158/1541-7786.MCR-08-0504
- ISSN
- 1541-7786
- Abstract
- The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs. MET amplification was recently found to be a mechanism of escape from the anticancer effect of EGFR inhibitors. In the present study, we investigated the means whereby MET affects sensitivity to EGFR-TKIs in PC-9 cells. Gefitinib- or eriotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance. Resistant cells also showed MET activation, although gene amplification was not detected. Furthermore, the induction of MET activity was not found to be associated with sensitivity to EGFR-TKIs. Interestingly, increased passage number without exposure to gefitinib or erlotinib caused MET activation, but this did not affect sensitivity to EGFR-TKIs. In addition, hepatocyte growth factor was found to block the ability of EGFR-TKIs to inhibit MET activation. However, sustained MET activation by hepatocyte growth factor did not modulate the cellular effects of gefitinib or erlotinib. Rather, activated MET enhanced migration and invasion abilities. Summarizing, MET activation may be acquired during cancer cell proliferation and enhances migratory and invasive abilities without affecting cellular sensitivity to EGFR-TKIs. Accordingly, the present study suggests that MET activation caused by factors other than MET gene amplification is not a suitable surrogate marker of resistance to EGFR-TKIs. (Mol Cancer Res 2009;7(10):1736-43)
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/119204)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.